Date:	6/19/2024	
Your Name:	Matthew Anderson	
Manuscript Title: [Recommendations for clinical implementation of blood-based biomarkers for Alzheimer disease		
Manuscript Number (if known):	[Click or tap here to enter text.]	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Image: State of the st	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	☑ None □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None [
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [⊠] I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Map A

Date:	9/20/2023	
Your Name:	Andreas Jeromin	
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease	
Manuscript Number (if known):	ADJ-D-23-01032	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None □ □ □ □ □ □	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None □ □ □ □ □ □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None [
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[□] None [ALZpath, Inc.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None ALZpath, Inc.	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	□ None Employee of ALZpath, Inc.	
Please place an "X" next to the following statement to indicate your agreement:			

Date:	6/19/2024	
Your Name:	J. Wesson Ashford, MD, PhD	
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease	
Manuscript Number (if known):	[Click or tap here to enter text.]	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	□ □ □ □	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	☑ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None □ □ □ □ □ □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None [
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	□ None Unpaid consultant to MemTrax, LLC	
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	19th June 2024
Your Name:	Sasha Bozeat
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease

Manuscript Number (if known):	Click or tap here to enter text
-------------------------------	---------------------------------

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work			of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x	None	Click the tab key to add additional rows.
			Time frame: past 36 month	s
contracts	Grants or contracts from any entity (if not	x	None	
	indicated in item #1 above).			
3	Royalties or licenses	x	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	x None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x None	
6	Payment for expert testimony	x None	
7	Support for attending meetings and/or travel	x None	
8	Patents planned, issued or pending	x None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x None	
11	Stock or stock options	x None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x None	
13	Other financial or non-financial interests	None I am an employee of Hoffman-La Roche and I own stock options of that company	
Please place an "X" next to the following statement to indicate your agreement: X I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	6/25/2024	
Your Name:	Samantha C. Burnham	
Manuscript Title: [Recommendations for clinical implementation of blood-based biomarkers for Alzh disease		
Manuscript Number (if known):	[Click or tap here to enter text.]	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Image: None Image: Image: past 36 months	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None □ □ □ □ □ □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	 □ None CSIRO: METHOD FOR DETECTION OF A NEUROLOGICAL DISEASE Publication number: 20140086836 	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None Eli Lilly	Stock holder
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	□ None Eli Lilly	Employee
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	Click or tap to enter a date.	
Your Name:]	Dr Chinedu Udeh-Momoh	
Manuscript Title: Recommendations for clinical implementation of blood-based biomarkers for Alz disease		
Manuscript Number (if known):	Click or tap here to enter text.	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	g of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None [Click the tab key to add additional rows.
		Time frame: past 36 month	15
2	Grants or contracts from any entity (if not indicated in item #1 above).	 None 2024 - MRC UKRI Applied Global Health award 2023 - Wellcome Leap Dynamic Resilience grant award 2023 - Alzheimer's Association Sex and Gender Differences Award 2023 - Davos Alzheimer's Collaborative Global Cohort Fund 2023 - Global Brain Health Institute Project Award 2022 - UK Defence and Security Accelerator, Veterans' Health Innovation Fund 	Payment made to institutionPayment made to institution
		2022 - RoseTrees Foundation Seedcorn award	Payment made to institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	⊠ None	
4	Consulting fees	□ None Braina nd Mind Institute, Aga Khan University, Kenya	Payment made to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	 None Dementia and Brain Aging in LMIC 2022 conference – Alzheimer's Association Competitive Travel Fellowship for oral presentation at the LMIC meeting in Nairobi, Kenya. Alzheimer's Association International conference (AAIC) 20222 – Alzheimer's Association Competitive Travel Fellowship for oral presentation at the AAIC meeting in San Diego, USA. 	Payment made to me Payment made to me
8	Patents planned, issued or pending	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None [
10	Leadership or fiduciary role in other board, society, committee or advocacy group,	 None Elected Trustee at British Society for Neuroendocrinology (roles: EDI Chair and Grants Committee member) Executive Committee member, Alzheimer's 	Unpaid role Unpaid role
	paid or unpaid	Association ISTAART Expert Committee member, NIH-Funded National Academies of Science, Engineering and Medicine (NASEM) project to determine research priorities for ADRD	Unpaid role
11	Stock or stock options	[⊠] None [
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	06/20/2024
Your Name:	Michelle M. Mielke
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease
Manuscript Number (if known):	ADI-D-24-00705

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	□ □ <t< td=""><td>Click the tab key to add additional rows.</td></t<>	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	NoneNIH: RF1 AG69052; RF1 AG077386; R01AG079397, U19 AG078109, U24 AG082930 DOD: W81XWH2110490 Alzheimer's Association Davos Alzheimer's Collaborative	To my institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑ None □ □ □ □	
4	Consulting fees	Image: State of the state	Money paid to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Discrete Novo Nordisk	Money paid to me
6	Payment for expert testimony	[⊠] None [
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid	Alzheimer's Drug Discovery Foundation	Money paid to me for grant review
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement:		

Date:	6/23/2024	
Your Name:	Daryl Rhys Jones	
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease	
Manuscript Number (if known):	Click or tap here to enter text.	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	□ □ □ □	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	 □ None I own stock options with AbbVie and Eisai who both have interest in Alzheimer's disease 	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [I] I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/20/2024	
Your Name:	John Dwyer	
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease	
Manuscript Number (if known):	[Click or tap here to enter text.]	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	[⊠] None [Click the tab key to add additional rows.
	_	Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	 None C2N, Quanterix, Fujirebio, Retispec Eli Lilly & Company, Biogen, Merck, Abbvie, 	Paid licensing fees to participate in GAP's BH1 biomarker study Paid licensing fees to participate in GAP's BH1 biomarker study Paid licensing fees to participate in GAP's BH1 biomarker study

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	 None President and Board Member of the Global Alzheimer's Foundation Board Member of Us Against Alzheimer's Board Member of Voices of Alzheimer's 	Full-time Officer of the Foundation No Compensation No Compensation

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Please place an "X" next to the following statement to indicate your agreement:			

Date:	6/25/2024
Your Name:	Dylan Young
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Image: None Image: CEOi CEOi Image: Display the second	Consulting fees in partnership with Guidehouse Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	☑ None □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None □ □ □ □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None [
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [I] I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date: 6/18/2024	
Your Name: Emily Scholler	
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease
Manuscript Number (if known):	[Click or tap here to enter text.]

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Image: None Image: Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Please place an "X" next to the following statement to indicate your agreement:			

Date:	6/18/2024		
Your Name:	Fabricio Ferreira de Oliveira	Recommendations for clinical implementation of blood- based biomarkers for Alzheimer's disease	
Manuscript Title:	r		

Manuscript Number (if known):	ADJ-D-24-00706
-------------------------------	----------------

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work		
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	None Image: Solution of the state of São Paulo Research Foundation FAPESP – The State of São Paulo Research Foundation	Click the tab key to add additional rows. s grant #2015/10109-5
3	Royalties or licenses	☑ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None Gerson Lehrman Group Atheneum Partners	Payments made to me. Payments made to me.
		Guidepoint Lionbridge	Payments made to me. Payments made to me.
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	 [⊠] None 	
7	Support for attending meetings and/or travel	None Alzheimer's Association International Conference – AAIC>23 (Amsterdam)	The Alzheimer's Association sponsored the conference registration and the airfare.
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board,	None American Academy of Neurology Global	Unpaid.
	society, committee or advocacy group, paid or unpaid	Strategies Subcommittee Awards Committee of the International Parkinson and Movement Society European Science Foundation Committee of	Unpaid. Payments made to me.
		Experts	ayments made to me.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Executive Committee Member, ISTAART Biofluid Based Biomarkers Professional Interest Area (Alzheimer's Association)	Unpaid.	
		Executive Committee Member, ISTAART Neuropsychiatric Syndromes Professional Interest Area (Alzheimer's Association)	Unpaid.	
11	Stock or stock options	⊠ None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	Image: None		
	services		·	
13	Other financial or non-financial interests	None Associate Editor, Clinical Neurology & Neurosurgery (Elsevier)	Payments made to me.	
		Associate Editor, Journal of Alzheimer's Disease – JAD (IOS Press)	Unpaid.	
		Associate Editor, Frontiers in Neuroscience (Frontiers Media)	Unpaid.	
		Academic Editor, Medicine [®] (Wolters Kluwer Health)	Unpaid.	
		Editorial Board Member, Neurology [®] (American Academy of Neurology)	Unpaid.	
		Editorial Board Member, Neurology Letters (Iran University of Medical Sciences)	Unpaid.	
		Grant Reviewer, University of Ljubljana (Slovenia)	Payments made to me.	
		Grant Reviewer, Institut Pasteur (France)	Unpaid.	
		Grant Reviewer, Ministry of Health (Brazil)	Unpaid.	
		Grant Reviewer, The State of São Paulo Research Foundation – FAPESP (Brazil)	Unpaid.	
		Grant Reviewer, The State of Rio Grande do Sul Research Foundation – FAPERGS (Brazil)	Unpaid.	
		Grant Reviewer, The State of Tocantins Research Foundation – FAPT (Brazil)	Unpaid.	
Please place an "X" next to the following statement to indicate your agreement:				

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	6/19/2024	
Your Name:	Oskar Hansson	
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease	
Manuscript Number (if known):	NA	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning Image: Since the initial planning Imag	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	[□] None	
		AC Immune BioArctic Biogen Bristol Meyer Squibb C2N Diagnostics Eisai Eli Lilly Fujirebio Merck Novartis Novo Nordisk Roche Sanofi	mememeinstituteme
		Siemens	me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	6/24/2024	
Your Name:	Drew Holzapfel	
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease	
Manuscript Number (if known):	Click or tap here to enter text.	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as ed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Director of CEOi, which supported	ed the formation of the Workgroup.

			e all entities with whom you have this ionship or indicate none (add rows as ed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [I] I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	6/20/2024	
Your Name:	Joel B. Braunstein	
Manuscript Title: Recommendations for clinical implementation of blood-based biomarkers for Alzheimer disease		
Manuscript Number (if known):	[Click or tap here to enter text.]	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Image: past 36 months	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	☑ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	 □ None Dr. Braunstein is an employee and shareholder of C2N Diagnostics 	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	 □ None □ Dr. Braunstein is an employee and shareholder of C2N Diagnostics 	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [\vec{A}] I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/18/2024	
Your Name:	Katherine Ann Partrick	
Manuscript Title: Recommendations for clinical implementation of blood-based biomarkers for Alzheimer disease		
Manuscript Number (if known):	[Click or tap here to enter text.]	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Payment received from Global CEO Initiative on Alzheimer's Disease for medical writing. Image: State of the s	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Payment received from Global CEO Initiative on Alzheimer's Disease for medical writing.	
6	Payment for expert testimony	[⊠] None [
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None [
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [I] I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/18/2024	
Your Name:	ARA S. KHACHATURIAN	
Manuscript Title: [Recommendations for clinical implementation of blood-based biomarkers for Alzheimer disease		
Manuscript Number (if known):	[Click or tap here to enter text.]	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Image: Prevent Alzheimer's Disease 20/20 Brain Watch Coalition Image: Disease 20/20 Imag	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None [
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	 □ None Prevent Alzheimer's Disease 20/20 Brain Watch Coalition 	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	 None Editor-in-Chief, Journal of Aging Research and Lifestyle Editor-in-Chief, Vitality, Medicine & Engineering Chair, Scientific Advisory Board, International Neurodegenerative Research Center 	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/20/2024	
Your Name:	Pei-Jung Lin	
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease	
Manuscript Number (if known):	[Click or tap here to enter text.]	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☑ None ☑ □ □ □ □ □	Click the tab key to add additional rows.
		Time frame: past 36 month	IS
2	Grants or contracts from	[□] None	
	any entity (if not	NIA	Research funds made to Tufts Medical Center
	indicated in item	Biogen	Research funds made to Tufts Medical Center
	#1 above).	Eisai	Research funds made to Tufts Medical Center
		Genentech/Roche	Research funds made to Tufts Medical Center
		Lilly	Research funds made to Tufts Medical Center
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None Lilly	Payments made to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None [
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Ple:	Please place an "X" next to the following statement to indicate your agreement: [I] I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/19/2024
Your Name:	Marwan Noel Sabbagh, MD
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ None	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past 36 monthImage: NonePI: R01AG059008SABBAGH, MARWAN (PI)09/01/18-05/31/24A Phase I Clinical Trial for the Assessment ofSafety, Tolerability, and Efficacy of Lenalidomidein Patients with Mild Cognitive Impairment Due toAlzheimer's DiseaseGC-2013717SABBAGH, MARWAN (PI)01/01/23-12/31/27Assessment of Lenalidomide for Alzheimer'sDiseaseLBDA1811MS	S

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		SABBAGH, MARWAN (PI) 05/15/17-04/30/23 Research Center of Excelence (RCOE) designation R01 AG073212 SABBAGH, MARWAN (PI) WILSON, JEFFREY (MPI) DECOURT, BORIS (MPI) Repurposing Siponimod for Alzheimer's Disease 4/1/21- 3/30/26 Site PI TRC-DS 1R61AG066543-01 (R61AG066543) Site PI:ADRC- 1P30AG072980-01 Site PI: ADNI-U19AG024904	
3	Royalties or licenses	None	
4	Consulting fees	 None Roche-Genentech, Eisai, Lily, Synaptogenix, Neuro Therapia, Signant Health, Novo Nordisk, Prothena, KeiferRx, Anavex, Cognito Therapeutics, GSK, Abbvie 	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	⊠ None	

		Name all entities with whom you have thisSpecifications/Comments (e.g., if payments wererelationship or indicate none (add rows as needed)made to you or to your institution)
8	Patents planned, issued or pending	☑ None □ □ □ □ □ □
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑ None □ □ □ □ □ □
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None EIP Pharma/CervoMed
11	Stock or stock options	None NeuroTau, Optimal Cognitive Health Company, Method Health, Versanum, Athira, TransDermix, Seq BioMarque, NeuroReserve, Lighthouse Pharmaceuticals, Alzheon, Reservoir Neuroscience
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non-financial interests	☑ None □ □ □ □ □ □
Plea	-	t to the following statement to indicate your agreement: answered every question and have not altered the wording of any of the questions on this form.

5 e|a|24

Date:	6/19/2024	
Your Name:	Soeren Mattke	
Manuscript Title: [Recommendations for clinical implementation of blood-based biomarkers for Alzheimer disease		
Manuscript Number (if known):	Click or tap here to enter text.	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Click the tab key to add additional rows. Click the tab key to add additional rows.	
2	Grants or contracts from any entity (if not indicated in item #1 above).	 □ None Biogen, C2N, Eisai, Roche 	Research contracts to USC
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None Biogen, C2N, Eisai, Roche/Genentech, Novo Nordisk	Personal consulting fees
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	[□] None Roche, Novartis, Novo Nordisk, Eisai, Eli Lilly	Honoraria for educational events
6	Payment for expert testimony	[⊠] None [
7	Support for attending meetings and/or travel	[□] None [Roche	Travel to AAIC 2023
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[□] None [Roche	Advisory Boards
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[□] None Senscio Systems	Board of Directors

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	 □ None [AiCure Technologies, Alzpath and Boston Millennia Partners 	Scientific advisory board
Plea [🖂]	-	xt to the following statement to indicate your agreem e answered every question and have not altered the word	

Date:	6/24/2024	
Your Name: Michael W. Weiner		
Manuscript Title: [Recommendations for clinical implementation of blood-based biomarkers in disease		
Manuscript Number (if known):	Click or tap here to enter text.	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	g of the work
1	All support for the present	[□] None	
	manuscript (e.g.,	NIH Grant: 5R01AG058676-02	Payments were made to my institution.
	funding, provision	NIH Grant: 2 U19 AG024904.16	Payments were made to my institution.
	of study materials,		Click the tab key to add additional rows.
	medical writing, article processing		
	charges, etc.)		
	No time limit for		
	this item.		
		Time frame: past 36 mont	ne
2	Grants or contracts from	□ None	
	any entity (if not	NIH Grant: 5U2CAG060426-04	Payments were made to my institution.
	indicated in item	NIH Grant: 1RF1AG059009-01	Payments were made to my institution.
	#1 above).	NIH Grant: R33 AG062867	Payments were made to my institution.
		NIH Grant: 1R01NS119651-01	Payments were made to my institution.
		NIH Grant: RF1AG062196	Payments were made to my institution.
		NIH Grant: R56AG075744-01A1	Payments were made to my institution.
		Additional support from Department of Defense (DOD)	Payments were made to my institution.
		Additional support from: California Department of Public Health (CDPH)	Payments were made to my institution.
		Additional support from: Siemens	Payments were made to my institution.
		Additional support from: Biogen	Payments were made to my institution.
		Additional support from: Hillblom Foundation	Payments were made to my institution.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Additional support from: Alzheimer's Association	Payments were made to my institution.
		Additional support from: Johnson & Johnson	Payments were made to my institution.
		Additional support from: Kevin and Connie Shanahan	Payments were made to my institution.
		Additional support from: GE	Payments were made to my institution.
		Additional support from: VUmc	Payments were made to my institution.
		Additional support from: Australian Catholic University (HBI-BHR)	Payments were made to my institution.
		Additional support from: The Stroke Foundation	Payments were made to my institution.
		Additional support from: Veterans Administration	Payments were made to my institution.
3	Royalties or licenses	⊠ None	
4	Consulting fees	□ None	
		Boxer Capital	Payment was made directly to me.
		Cerecin	Payment was made directly to me.
		Clario/BioClinica	Payment was made directly to me.
		Dementia Society of Japan	Payment was made directly to me.
		Eisai	Payment was made directly to me.
		Guidepoint	Payment was made directly to me.
		Health and Wellness Partners	Payment was made directly to me.
		Indiana U.	Payment was made directly to me.
		LCN Consulting	Payment was made directly to me.
		Merck Sharp & Dohme Corp.	Payment was made directly to me.
		Duke U.	Payment was made directly to me.
		Prova Education	Payment was made directly to me.
		T3D Therapeutics	Payment was made directly to me.
		University of Southern CA (USC)	Payment was made directly to me.
		WebMD	Payment was made directly to me.
		MEDA Corp.	Payment was made directly to me.
5	Payment or honoraria for	□ None	
	lectures, presentations,	China Association for Alzheimer's Disease (CAAD)	Payment was made directly to me.
	speakers	Taipei Medical University	Payment was made directly to me.
	bureaus,	Cleveland Clinic	Payment was made directly to me.
	manuscript	AD/PD Congress	Payment was made directly to me.
1	writing or	Foundation of Learning; Health Society (Japan)	Payment was made directly to me.
	educational	INSPIRE Project; U. Toulouse	Payment was made directly to me.
	events	Japan Society for Dementia Research	Payment was made directly to me.
		Korean Dementia Society	Payment was made directly to me.
		Merck Sharp & Dohme Corp.,	Payment was made directly to me.
		National Center for Geriatrics and Gerontology (NCGG; Japan	Payment was made directly to me.
		University of Southern California (USC)	Payment was made directly to me.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
6	Payment for expert testimony	[⊠] None	
7	Support for attending	□ None	
	meetings and/or travel	[AD/PD Congress	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Cleveland Clinic	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		CTAD Congress	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Foundation of Learning; Health Society (Japan)	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		INSPIRE Project; U. Toulouse	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Japan Society for Dementia Research	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Korean Dementia Society	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Merck Sharp & Dohme Corp.,	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		National Center for Geriatrics and Gerontology (NCGG; Japan University of Southern California (USC)	Payment was made either directly to the travel accommodations provider, or reimbursed to me.Payment was made either directly to the travel
			accommodations provider, or reimbursed to me.
8	Patents planned, issued or	[⊠] None	
	pending		
9	Participation on a Data Safety	□ None	
	Monitoring Board or Advisory	ADNI Scientific Advisory Board UCSF Committee for Human Research	Leadership Committee Member
	Board		
10	Leadership or fiduciary role in	Diamon Di	
	other board, society,	UCSF Inclusion Diversity Equity & Awareness Committee	Leadership
	committee or advocacy group, paid or unpaid	Diversity Task Force of the Alzheimer's Disease Neuroimaging Initiative (ADNI)	Leadership

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None	
		Alzeca	Stock options held.
		Alzheon, Inc.	Stock options held.
		ALZPath	Stock options held.
		Anven	Stock options held.
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None [
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/24/2024
Your Name:	Mark Monane
Manuscript Title:	
Manuscript Number (if known):	CIRecommendations for implementation of blood-based biomarkers for Alzheimer's disease

In the interest of transparency, w

content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	· · · · · · · · · · · · · · · · · · ·	Time frame: past 36 month	15
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	C2N Diagnostics, LLC	Paid to me
5	Payment or honoraria for lectures, presentations,	⊠ None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or	None	
	travel	C2N Diagnostics, LLC	Paid to me
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring	None	!
	Board or Advisory Board		-
10	Leadership or fiduciary role in other board, society, committee or	None	
	advocacy group, paid or unpaid		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock	None		
		C2N Diagnostics, LLC	Paid to me	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None		
13	Other financial or non-financial interests	⊠ None		
Plea 🛛	Please place an "X" next to the following statement to indicate your agreement:			

Date: 8/26/2021	
Your Name:	James F Murray
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease
Manuscript Number (if known):	[Click or tap here to enter text.]

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g.,	Davos Alzheimer's Collaborative – System	Time for meetings was supported as part of my
	funding, provision	Preparedness	regular duties
	of study materials, medical writing,		Click the tab key to add additional rows.
	article processing charges, etc.) No time limit for this item.		
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	 □ None □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	
3	Royalties or licenses	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None Davos Alzheimer's Collaborative – System Preparedness	Time for meetings was supported as part of my regular duties
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	Davos Alzheimer's Collaborative – System Preparedness	Time for meetings was supported as part of my regular duties
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None [
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None Eli Lilly and Company, Inc	Retired Stock Holder
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	25 June 2024	
Your Name:	Richard Batrla	
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease	
Manuscript Number (if known):	Click or tap here to enter text.	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		rela	ne all entities with whom you have this tionship or indicate none (add rows as ded)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	; of the work
1	All support for the present manuscript (e.g., funding, provision	x	None	
	of study			
	materials, medical			Click the tab key to add additional rows.
2	writing, article processing charges, etc.) No time limit for this item. Grants or		Time frame: past 36 month	ns
	contracts from any entity (if not	X	None	
	indicated in item			
	#1 above).			
3	Royalties or licenses	x	None	
		L		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	x None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Employment by Eisai - Pharmaceutical company manufacturing Lecanemab	
6	Payment for expert testimony	x None	
7	Support for attending meetings and/or travel	x None	
8	Patents planned, issued or pending	x None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	x None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x None	
13	Other financial or non-financial interests	x None	
Please place an "X" next to the following statement to indicate your agreement: x I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	6/20/2024	
Your Name:	Allyson C. Rosen	
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease	
Manuscript Number (if known):	[Click or tap here to enter text.]	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work		of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Image: None Image: Image: Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Image:	
3	Royalties or licenses	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None □ □ □ □ □ □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	[⊠] None [
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	 □ None Advisory Group on Risk Evidence for Dementia 	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Ple:	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/19/2024	
Your Name:	Suzanne E. Schindler	
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease	
Manuscript Number (if known):	Click or tap here to enter text.	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work		of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Image: None Image: Image: Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	 □ None Barnes-Jewish Hospital Foundation National Institute on Aging grant R01AG070941 (SE Schindler) 	
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	[□] None	
		Eisai	Consulting fees for advisory boards on blood biomarkers and biomarker education for providers
		Novo Nordisk	Consulting fees for advisory board on blood biomarkers and biomarker education for providers
5	Payment or honoraria for	[□] None	
	lectures,	Eli Lilly	Honoraria for presenting lecture
	presentations, speakers bureaus, manuscript writing or	University of Wisconsin, St. Luke's Hospital, Houston Methodist Medical Center, Weill Cornell, University of Massachusetts, Zucker School of Medicine, Medscape, (ATRI)/University of Southern California	Honoraria for presenting lectures
	educational	University of Washington	Honoraria for serving on the Alzheimer Disease Center Clinical Task Force
		University of Indiana	Honoraria for serving on the National Centralized Repository for Alzheimer's Disease biospecimen review committee
6	Payment for expert testimony	[⊠] None	
7	Support for attending	[□] None	
	meetings and/or travel	National Institute on Aging grant R01AG070941 (SE Schindler)	Travel support is included in NIH grant
		Alzheimer's Association	Travel support for 2023 AAIC and 2023 Research Roundtable
		US Against Alzheimer's	Travel support for Lausanne X
8	Patents planned, issued or	[⊠] None	
	pending		
9	Participation on a Data Safety	[□] None	
	Monitoring Board or Advisory Board	World Health Organization	Participating in a committee advising the WHO on preferred product characteristics for fluid biomarkers of Alzheimer disease.
		University of Washington	Served on the Alzheimer Disease Center Clinical Task Force that is revising the data collection set used by all ADRCs; attended meetings every 2 weeks and did additional research and writing.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		University of Indiana	Reviewing sample requests for the National Centralized Repository for Alzheimer's Disease biospecimen review committee.
		University of Michigan	Member of the External Advisory Committee reviewing the Michigan ADRC and providing recommendations.
10	Leadership or fiduciary role in	[□] None	
	other board, society, committee or	Greater Missouri Chapter of the Alzheimer's Association	Board member working to support local efforts to raise funds for the Alzheimer's Association and advise them on research and support.
	advocacy group, paid or unpaid	Global CEO initiative workgroup on Blood-Based Biomarkers	Co-leader of workgroup tasked with developing performance standards for blood-based biomarkers; attended weekly meetings for ~6 months and worked on writing paper.
		Advisory Group on Risk Evaluation Education for Dementia	Participated in monthly calls discussing the ethical and legal implications of research on dementia that could allow for prediction of individual risk.
		Foundation for the National Institutes of Health Biomarkers Consortium	Project team member participating in planning head-to-head studies of blood-based biomarker assays.
11	Stock or stock options	[⊠] None	
12	Receipt of equipment,	[□] None	
	materials, drugs, medical writing, gifts or other services	C2N Diagnostics	Plasma Ab42/Ab40 data was provided to Washington University by C2N Diagnostics at no cost. No payments/research funding was provided by C2N Diagnostics. No gifts/financial incentives of any kind have been provided to Dr. Schindler by C2N Diagnostics.
12			
13	Other financial or non-financial interests	⊠ None	
		·	
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have	e answered every question and have not altered the work	ding of any of the questions on this form.

Date:	6/24/2024
Your Name:	Eli Shobin
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease
Manuscript Number (if known):	[Click or tap here to enter text.]

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present	[□] None	
	manuscript (e.g.,	Biogen	Employer
	funding, provision of study materials,		Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	☑ None ☑ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	□ None Biogen	Employer
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None Alzheimer's Drug Discovery Foundation	Head of the Diagnostics Accelerator

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	□ None Biogen Eli Lilly Abbvie ■		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None		
13	Other financial or non-financial interests	[⊠] None		
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [I] I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	6/18/2024
Your Name:	Jamie Tyrone
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease
Manuscript Number (if known):	[Click or tap here to enter text.]

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None Advisory Group on Risk Evidence for Dementia	Co-Chairperson for Stakeholder Sub-committee

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	[⊠] None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None		
13	Other financial or non-financial interests	[⊠] None		
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement:			

Date:	6/20/2024
Your Name:	Lawren VandeVrede
Manuscript Title:	Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work		
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	□ None NIH K23AG073514 Alzheimer's Association Alzheimer's Association Shenandoah Foundation Shenandoah Foundation Time frame: past 36 month ☑ None ☑ None	Click the tab key to add additional rows.
3	Royalties or licenses	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None □ □ □ □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None [
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement:		

Date:	6/24/2024	
Your Name:	George Vradenburg	
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease	
Manuscript Number (if known):	Click or tap here to enter text.	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as ed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
	ļ	 Time frame: past 36 month	15
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	D None Convener of CEOi, which supported the formation of	the Workgroup.

			e all entities with whom you have this ionship or indicate none (add rows as ed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea [🖂]	Please place an "X" next to the following statement to indicate your agreement: [X] I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	6/25/2024	
Your Name:	Joan Weiss, PhD, RN, CRNP, FAAN	
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease	
Manuscript Number (if known):	[Click or tap here to enter text.]	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning None Image: Since the initial planning Image: Since the initial planning	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Ple:	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/19/2024
Your Name:	Deanna R Willis MD MBA
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease
Manuscript Number (if known):	Click or tan here to enter text

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Davos Alzheimer's Collaborative	Payments to Indiana University for services of Being Principal Investigator on a research study They funded that was on early detection in primary care. That work is NOT specifically referenced in this manuscript
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	Davos Alzheimer's Collaborative	As noted under #1 to attend Davos Collaborative meetings
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None Voices of Alzheimer's	Assisting as unpaid advisor to help advocacy efforts through communication with primary care physicians.

.

.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	D None	
	opici i	Resonea	Stock owner in company using FDA cleared mobile app to detect sleep apnea. Company no longer exists.
		Topera	Stock owner in company working to improve diagnosis and treatment of atrial fibrillation. Company sold to Abbott. No longer receiving payments from sale.
12	Receipt of equipment,	□ None	
	materials, drugs, medical writing, gifts or other services	Linus Health	Provided in kind devices and software for Davos Alzheimer's Collaborative of Digital cognitive assessment device
		C2N Diagnostics	Provided in kind blood based biomarker testing for Davos Alzheimer's Collaborative (PrecivityAD)
13	Other financial or non-financial	None None	
	interests		

10/19/24 Deanna F. Will's

Date:	6/18/2024
Your Name:	Yan Helen Hu
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease
Manuscript Number (if known):	[Click or tap here to enter text.]

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Please place an "X" next to the following statement to indicate your agreement: [X] I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	6/25/2024
Your Name:	Zul Merali
Manuscript Title:	Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease
Manuscript Number (if known):	[Click or tap here to enter text.]

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning Image: Since the initial planning Imag	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	 □ None □ Davos Alzheimer's Collaborative; □ Wellcome Leap 	
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	□ None Aga Khan University	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None □ □	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	 □ None Founding Director, Brain and Mind Institute, Aga Khan University 	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Please place an "X" next to the following statement to indicate your agreement: $[\square]$ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			